Maxalt (or preferably Maxalt MLT which melts in your mouth at same price) is very good. It is in triptan family of drugs. You get only 9 to a Rx but since one makes me sleep, I break it in half and it works well, and I get 18 that way.
Bad news it is very expensive, but my insurance covers all but $30. Good news is that I read a reliable source that said it probably would be generic in December.
Lately however there are sometimes it doesn't get rid of all the headache, and I have had to take something else like Fioricet or Fiorinal or Ibuprophen in an hour or 2.
PCPerson,
Hello and welcome! It would be great to see a generic form of Maxalt that soon, and I hope your source is correct.
However, according to the FDA, the earliest a generic form would be available is 2012. Mylan pharmaceuticals has a tentative approval for generic Maxalt, but those are often granted several years before the generics can be marketed.
Imitrex tablets should be the first tablet form generic triptan, and should be available next year. Nine companies have tentative approval of generic sumatriptan (Imitrex). The first of those tentative approvals was granted in 2005.
Not trying to be negative, but thought I'd share the info I have.
On the subject of the Maxalt not always working -- have you tried all the other triptans? If not, it would be worth talking with your doctor about trying them.
Welcome again,
Teri
I was wrong--it IS Imitrex, not Maxalt. Thanks for pointing that out.! I looked up what I had printed & saved. It was off www.njbz.com (New Jersey business)
Ranbaxy to Sell Copycat Migraine Med By Thomas Gaudio 1/21/2008
Generic drug maker Ranbaxy Laboratories Limited said today that it has settled the issues surrounding its possible patent litigation with GlaxoSmithKline related to Imitrex, the British drug maker's medicine for migraine headaches.
The settlement provides that India-based Ranbaxy, which has its U.S. headquarters in Princeton, may distribute sumatriptan succinate tablets, a generic version of Imitrex tablets, in three dosages in the United States. The expected launch date is December. Additional terms of the deal were not disclosed.
Annual sales for Imitrex are $985 million, according to statistics cited by Ranbaxy. Imitrex is also sold as a nasal spray and an injection.